Metastatic Triple-negative Breast Cancer

Clinical Oncology

Volumn 23, Issue 9, 2011, Pages 587-600

  Rakha, E A ^a   Chan, S ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Breast cancer; Metastasis; Prognosis; Targeted therapy; Triple negative

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; BICALUTAMIDE; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; ESTRADIOL; ESTROGEN RECEPTOR; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GEMCITABINE; INIPARIB; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PANITUMUMAB; PLATINUM DERIVATIVE; PROGESTERONE RECEPTOR; RAPAMYCIN; SUNITINIB; VELIPARIB;

ADVANCED CANCER; ARTICLE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; DNA CROSS LINKING; DNA REPAIR; DRUG MEGADOSE; DRUG WITHDRAWAL; GENE MUTATION; HETEROZYGOSITY LOSS; HETEROZYGOTE; HUMAN; INTRADUCTAL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MAMMOGRAPHY; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE C MYC; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT; VISCERAL METASTASIS;

BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 80053384610     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2011.03.013     Document Type: Article

References (109)

1. Haffty B.G., Yang Q., Reiss M., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006, 24:5652-5657.
2. Kwan M.L., Kushi L.H., Weltzien E., et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 2009, 11. R31.
3. Rakha E.A., Reis-Filho J.S., Ellis I.O. Basal-like breast cancer: a critical review. J Clin Oncol 2008, 26:2568-2581.
4. Galea M.H., Blamey R.W., Elston C.E., Ellis I.O. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992, 22:207-219.
5. Gluz O., Liedtke C., Gottschalk N., et al. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009, 20:1913-1927.
6. Rakha E.A., El-Sayed M.E., Green A.R., et al. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109:25-32.
7. Cheang M.C., Voduc D., Bajdik C., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14:1368-1376.
8. Anderson W.F., Chatterjee N., Ershler W.B., Brawley O.W. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002, 76:27-36.
9. Rakha E.A., El-Sayed M.E., Green A.R., et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007, 25:4772-4778.
10. Prat A., Baselga J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 2008, 5:531-542.
11. Kaplan H.G., Malmgren J.A. Impact of triple negative phenotype on breast cancer prognosis. Breast J 2008, 14:456-463.
12. Cheang M.C., Chia S.K., Voduc D., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750.
13. Azambuja E., Durbecq V., Rosa D.D., et al. HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. Ann Oncol 2008, 19:223-232.
14. Dent R., Trudeau M., Pritchard K.I., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434.
15. Reis-Filho J.S., Tutt A.N. Triple negative tumours: a critical review. Histopathology 2008, 52:108-118.
16. Turner N.C., Reis-Filho J.S. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006, 25:5846-5853.
17. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
18. Al Tamimi D.M., Shawarby M.A., Ahmed A., et al. Protein expression profile and prevalence pattern of the molecular classes of breast cancer - a Saudi population based study. BMC Cancer 2010, 10:223.
19. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
20. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423.
21. Cleator S., Heller W., Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007, 8:235-244.
22. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancers Study. JAMA 2006, 295:2492-2502.
23. Hammond M.E., Hayes D.F., Dowsett M., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795.
24. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
25. Lin N.U., Vanderplas A., Hughes M.E., et al. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). J Clin Oncol 2009, 27. abstract 543.
26. Thike A.A., Cheok P.Y., Jara-Lazaro A.R., et al. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 2010, 23:123-133.
27. Collett K., Stefansson I.M., Eide J., et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005, 14:1108-1112.
28. Yang W.T., Dryden M., Broglio K., et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 2008, 111:405-410.
29. Au-Yong I.T., Evans A.J., Taneja S., et al. Sonographic correlations with the new molecular classification of invasive breast cancer. Eur Radiol 2009, 19:2342-2348.
30. Chen J.H., Agrawal G., Feig B., et al. Triple-negative breast cancer: MRI features in 29 patients. Ann Oncol 2007, 18:2042-2043.
31. Uematsu T., Kasami M., Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology 2009, 250:638-647.
32. Basu S., Chen W., Tchou J., et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 2008, 112:995-1000.
33. Marginean F., Rakha E.A., Ho B.C., et al. Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast. Mod Pathol 2010, 23:1357-1363.
34. Banerjee S., Reis-Filho J.S., Ashley S., et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 2006, 59:729-735.
35. Hugh J., Hanson J., Cheang M.C., et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009, 27:1168-1176.
36. Dabbs D.J., Chivukula M., Carter G., Bhargava R. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol 2006, 19:1506-1511.
37. Kusinska R., Potemski P., Jesionek-Kupnicka D., Kordek R. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma - relation with grade, stage, estrogen receptor and HER2. Pol J Pathol 2005, 56:107-110.
38. Tischkowitz M., Brunet J.S., Begin L.R., et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007, 7:134.
39. Crabb S.J., Cheang M.C., Leung S., et al. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer 2008, 8:249-256.
40. Tan D.S., Marchió C., Jones R.L. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008, 111:24-44.
41. Seewaldt V.L., Scott V. Images in clinical medicine. Rapid progression of basal-type breast cancer. N Engl J Med 2007, 356. e12.
42. Rakha E.A., Elsheikh S.E., Aleskandarany M.A., et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009, 15:2302-2310.
43. Jumppanen M., Gruvberger-Saal S., Kauraniemi P., et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 2007, 9. R16.
44. Shakya R., Szabolcs M., McCarthy E., et al. The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression. Proc Natl Acad Sci USA 2008, 105:7040-7045.
45. Langerod A., Zhao H., Borgan O., et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007, 9. R30.
46. Subhawong A.P., Subhawong T., Nassar H., et al. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol 2009, 33:163-175.
47. Gauthier M.L., Berman H.K., Miller C., et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 2007, 12:479-491.
48. Reis-Filho J., Pinheiro C., Lambros M., et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 2006, 209:445-453.
49. Gilbert J.A., Goetz M.P., Reynolds C.A., et al. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther 2008, 7:944-951.
50. Rakha E.A., Tan D.S., Foulkes W.D., et al. Are triple-negative tumours and basal-like breast cancer synonymous?. Breast Cancer Res 2007, 9:404.
51. Bertucci F., Finetti P., Cervera N., et al. How basal are triple-negative breast cancers?. Int J Cancer 2008, 123:236-240.
52. Natrajan R., Lambros M.B., Rodriguez-Pinilla S.M., et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009, 15:2711-2722.
53. Bergamaschi A., Kim Y.H., Wang P., et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006, 45:1033-1040.
54. Wang Z.C., Lin M., Wei L.J., et al. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 2004, 64:64-71.
55. McCabe N., Turner N.C., Lord C.J., et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006, 66:8109-8115.
56. Hedenfalk I., Duggan D., Chen Y., et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001, 344:539-548.
57. Kandel M.J., Stadler Z., Masciari S., et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). J Clin Oncol 2006, 24. abstract 508.
58. Nofech-Mozes S., Trudeau M., Kahn H.K., et al. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat 2009, 118:131-137.
59. Azoulay S., Lae M., Freneaux P., et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol 2005, 18:1623-1631.
60. Rakha E.A., Putti T.C., Abd El-Rehim D.M., et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006, 208:495-506.
61. Largillier R., Ferrero J.M., Doyen J., et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 2008, 19:2012-2019.
62. Miles D.W., Chan A., Dirix L.Y., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
63. Fulford L.G., Easton D.F., Reis-Filho J.S., et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006, 49:22-34.
64. De Giorgi U., Rosti G., Frassineti L., et al. High-dose chemotherapy for triple negative breast cancer. Ann Oncol 2007, 18:202-203.
65. Kaplan H.G., Malmgren J.A., Atwood M.K. T1N0 triple negative breast cancer: adjuvant chemotherapy treatment and risk of recurrence. Breast J 2009, 15:454-460.
66. Di Leo A., Isola J., Piette F., et al. A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Breast Cancer Res Treat 2008, 107. abstract 705.
67. Cheang M., Chia S.K., Tu D., et al. Anthracyclines in basal breast cancer: the NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol 2009, 27:519.
68. Rodriguez-Pinilla S.M., Sarrio D., Honrado E., et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006, 12:1533-1539.
69. Sirohi B., Arnedos M., Popat S., et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008, 19:1847-1852.
70. Byrski T., Gronwald J., Huzarski T., et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010, 28:375-379.
71. Rottenberg S., Nygren A.O., Pajic M., et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 2007, 104:12117-12122.
72. Fourquet A., Stoppa-Lyonnet D., Kirova Y.M., et al. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status. Am J Clin Oncol 2009, 32:127-131.
73. Kyndi M., Sorensen F.B., Knudsen H., et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 2008, 26:1419-1426.
74. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:687-717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
75. Tsutsui S., Ohno S., Murakami S., Hachitanda Y., Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002, 71:67-75.
76. Agrawal A., Gutteridge E., Gee J.M., et al. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer 2005, 12(Suppl. 1):S135-144.
77. Kurebayashi J., Okubo S., Yamamoto Y., Sonoo H. Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer. Breast Cancer 2004, 11:38-41.
78. Irvin W.J., Carey L.A. What is triple-negative breast cancer?. Eur J Cancer 2008, 44:2799-2805.
79. Dogu G.G., Ozkan M., Ozturk F., et al. Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin. Med Oncol 2010, 27:34-39.
80. Mendelsohn J., Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006, 33:369-385.
81. Oliveras-Ferraros C., Vazquez-Martin A., Lopez-Bonet E., et al. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. Int J Oncol 2008, 33:1165-1176.
82. O'Shaughnessy J., Weckstein D.J., Vukelja S.J. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007, 106(S1):S32. abstract 308 (presentation).
83. Eppenberger U., Kueng W., Schlaeppi J.M., et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998, 16:3129-3136.
84. Linderholm B.K., Hellborg H., Johansson U., et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 2009, 20:1639-1646.
85. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
86. Robert N.J., Dieras V., Glaspy J., et al. RIBBON-1: randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). ASCO Annual Meeting 2009, abstract 1005.
87. Ryan P.D., Tung N.M., Isakoff S.J., et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J Clin Oncol 2009, 27. abstract 551.
88. Burstein H.J., Elias A.D., Rugo H.S., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008, 26:1810-1816.
89. Aulmann S., Adler N., Rom J., et al. c-myc amplifications in primary breast carcinomas and their local recurrences. J Clin Pathol 2006, 59:424-428.
90. Grushko T.A., Dignam J.J., Das S., et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 2004, 10:499-507.
91. Rodriguez-Pinilla S.M., Jones R.L., Lambros M.B., et al. MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J Clin Pathol 2007, 60:1017-1023.
92. Burgess D.J., Doles J., Zender L., et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA 2008, 105:9053-9058.
93. Bouchalova K., Cizkova M., Cwiertka K., et al. Triple negative breast cancer - current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009, 153:13-17.
94. Knoop A.S., Knudsen H., Balslev E., et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005, 23:7483-7490.
95. Chalmers A.J. The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull 2009, 89:23-40.
96. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
97. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
98. Fong P.C., Yap T.A., Boss D.S., et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010, 28:2512-2519.
99. Hashimoto K., Tamura K. Breakthrough breast cancer treatment - PARP inhibitor, BRCA, and triple negative breast cancer. Gan To Kagaku Ryoho 2010, 37:1187-1191.
100. Mendes-Pereira A.M., Martin S.A., Brough R., et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009, 1:315-322.
101. Ratnam K., Low J.A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007, 13:1383-1388.
102. O'Shaughnessy J., Osborne C., Pippen J.E., et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011, 364:205-214.
103. Tutt A., Robson M., Garber J.E., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
104. Edwards S.L., Brough R., Lord C.J., et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451:1111-1115.
105. Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006, 5:671-688.
106. Hochgrafe F., Zhang L., O'Toole S.A., et al. Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells. Cancer Res 2010, 70:9391-9401.
107. Finn R.S., Dering J., Ginther C., et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007, 105:319-326.
108. Caldas-Lopes E., Cerchietti L., Ahn J.H., et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci USA 2009, 106:8368-8373.
109. Bagatell R., Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 2004, 3:1021-1030.